Pediatric Acute Osteomyelitis

Neonates are flagged repeatedly above — transphyseal vessels in infants under about 18 months, GBS and E. coli as pathogens, and "transphyseal spread in neonates" as a complication — but neonatal osteomyelitis behaves so differently from the older child that it deserves its own treatment.

Why it is different

• Vascular anatomy: in infants up to roughly 12 to 18 months, transphyseal vessels still cross the open physis, so infection readily spreads metaphysis → epiphysis → joint. The physis is therefore not the protective barrier it is in older children, giving a high rate of concomitant septic arthritis and a real risk of growth-plate (chondro-epiphyseal) damage and later deformity.
• Multifocality: neonatal disease is frequently multifocal, so finding one site does not exclude others — have a low threshold for whole-body or multi-site imaging.

Why it is easily missed

• The classic localising signs are blunted. The baby may simply be irritable, feeding poorly or septic, with pseudoparalysis (refusal to move a limb) and pain on handling/nappy changes as the only musculoskeletal clue. Fever and inflammatory markers can be normal or only mildly raised, so a high index of suspicion is essential.

Pathogens and treatment differences

• Cover the neonatal organisms — Group B Streptococcus, S. aureus, and Gram-negatives such as E. coli — rather than the older-child spectrum; choose empirical antibiotics accordingly and involve neonatology.
• Because joint involvement and physeal damage are common, the threshold for joint aspiration/washout and for imaging the adjacent joint is lower, and long-term follow-up for growth disturbance is mandatory.

Pelvic Osteomyelitis: Specifically tricky. Often presents as deep hip/abdominal pain. MRI essential. May need prolonged antibiotics. (Detailed pelvic-OM work-up is covered in the dedicated paediatric pelvic osteomyelitis topic.)

The complication table lists DVT and the outcomes section notes that "MRSA is more aggressive, higher DVT risk" — this association deserves to be explicit because it identifies the genuinely sick child and changes management.

The severe-disease phenotype

• A subset of acute haematogenous osteomyelitis — typically virulent S. aureus, and especially community-acquired MRSA carrying the Panton-Valentine leukocidin (PVL) toxin — produces a far more aggressive illness: higher fever and CRP, larger and multifocal abscesses, myositis, and a markedly higher rate of complications and surgery.
• A hallmark is adjacent deep vein thrombosis (DVT) in the limb segment next to the infected bone, and from there septic pulmonary emboli — seeding the lungs with multiple nodular/cavitating lesions, causing respiratory deterioration that can mimic pneumonia.

Why it matters

• In a child with osteomyelitis who is unusually toxic, has a swollen limb, or deteriorates with chest signs, actively look for DVT (Doppler ultrasound) and septic emboli (chest imaging) — do not attribute breathlessness to "just the sepsis."
• Management escalates accordingly: MRSA-active antibiotics, aggressive source control of the larger collections these children develop, multidisciplinary input, and consideration of anticoagulation for established DVT.

• Antibiotics: Guided by culture sensitivities. Monitor CRP weekly.
• Immobilization: Splint/Cast for comfort and to prevent pathologic fracture.
• PICC Line: For long-term IV (if oral not suitable/available).
• Follow-up: X-rays to ensure healing, monitor growth.

• Uncomplicated: Excellent prognosis with antibiotics.
• MRSA: More aggressive, higher DVT risk, often needs surgery.
• Chronic OM: Difficult to eradicate. Recurrence common.

Global epidemiology

• Incidence roughly 1 in 5,000 to 1 in 10,000 children/year in high-income settings; higher burden and later presentation (more chronic OM) in low-resource regions.
• Kingella kingae predominates in children 6-48 months in PCR-equipped centres; S. aureus predominates in older children worldwide. CA-MRSA proportion varies sharply by region and drives empirical choices.

Practice variation (high- vs limited-resource)

• High-resource: MRI-led diagnosis, PCR microbiology, early IV-to-oral switch, outpatient/ambulatory IV (e.g. PICC) where oral not feasible, short total courses.
• Limited-resource: later presentation, more chronic OM and sequestra, greater reliance on radiographs/ultrasound and surgical debridement, longer parenteral therapy.
• Registries: no dedicated paediatric OM implant registry; surveillance comes from national paediatric infection networks and antimicrobial-resistance programmes that track local S. aureus/MRSA rates guiding empirical therapy.